Brant Point Investment Management LLC Takes Position in Phibro Animal Health Corporation $PAHC

Key Points

• Brant Point Investment Management LLC invested approximately $2.22 million in Phibro Animal Health Corporation, acquiring 103,724 shares, which represents about 0.26% of the company.
• Phibro announced a quarterly dividend of $0.12 per share, scheduled for payment on September 24th, with an annualized yield of 1.5%.
• Recent earnings reports showed Phibro exceeding analyst forecasts with a net margin of 2.68% and a revenue of $378.70 million for the quarter.

Brant Point Investment Management LLC bought a new position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 103,724 shares of the company's stock, valued at approximately $2,216,000. Brant Point Investment Management LLC owned approximately 0.26% of Phibro Animal Health at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PAHC. Point72 Asia Singapore Pte. Ltd. bought a new stake in Phibro Animal Health during the fourth quarter worth approximately $29,000. National Bank of Canada FI bought a new stake in Phibro Animal Health during the first quarter worth approximately $30,000. Lazard Asset Management LLC raised its holdings in Phibro Animal Health by 2,739.7% during the fourth quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock worth $34,000 after purchasing an additional 1,589 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in Phibro Animal Health during the fourth quarter worth approximately $69,000. Finally, Virtus Fund Advisers LLC bought a new stake in Phibro Animal Health during the fourth quarter worth approximately $69,000. Institutional investors own 99.34% of the company's stock.

Phibro Animal Health Stock Down 3.6%

NASDAQ:PAHC traded down $1.39 during trading hours on Monday, hitting $37.07. 644,926 shares of the stock traded hands, compared to its average volume of 323,934. The firm has a 50 day moving average price of $29.34 and a 200 day moving average price of $24.45. The company has a current ratio of 2.76, a quick ratio of 1.25 and a debt-to-equity ratio of 2.46. Phibro Animal Health Corporation has a fifty-two week low of $16.16 and a fifty-two week high of $38.83. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of 31.42, a PEG ratio of 0.54 and a beta of 0.88.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.05. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. The company had revenue of $378.70 million for the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. Equities research analysts anticipate that Phibro Animal Health Corporation will post 1.95 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 24th. Stockholders of record on Wednesday, September 3rd will be issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.3%. The ex-dividend date is Wednesday, September 3rd. Phibro Animal Health's payout ratio is currently 40.68%.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on PAHC. Zacks Research cut Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a report on Thursday. Wall Street Zen raised Phibro Animal Health from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Morgan Stanley set a $34.00 price target on Phibro Animal Health in a report on Thursday. BNP Paribas raised Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. Finally, BNP Paribas Exane raised Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target on the stock in a report on Monday, June 16th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and an average target price of $28.40.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.